Home/Opthea/Stuart Mudge

SM

Stuart Mudge

Chief Operating Officer

Therapeutic Areas

Rare Disease (Pulmonary)Ophthalmology

Opthea Pipeline

Drug	Indication	Phase
Sozinibercept (OPT-302)	Lymphangioleiomyomatosis (LAM)	Phase 2 (Planned)

Leadership Team at Opthea

Jeremy M. Levin

Chairman of the Board

Non-Executive Director and Chair of Remuneration Committee

Chief Technology Officer

Chief Finance Officer

View full Opthea profile